ReviewFrontiers in pharmacology2017
Anticancer Activities of Surfactin and Potential Application of Nanotechnology Assisted Surfactin Delivery.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 204 citations in OpenAlex.
- The Surfactin-Like Lipopeptides FromFrontiers in bioengineering and biotechnology · 2021Pooled it
- Potential Use of Microbial Surfactant in Microemulsion Drug Delivery System: A Systematic Review.Drug design, development and therapy · 2020Pooled it
- Biosurfactant-Based Interventions for Improving Lung Function and Controlling Inflammation.Pharmaceutical research · 2026Review
- Promoter Engineering of the Surfactin Operon Enhances Surfactin Production in the Environmental Strain Bacillus subtilis RI4914.Current microbiology · 2026Article
- Immunomodulatory Properties of the Cyclic Lipopeptide Surfactin.Journal of microbiology and biotechnology · 2026Review
- Bacillus mojavensis postbiotics: transcriptomic and anticancer effects in colon cancer cells.AMB Express · 2026Article
- Anticancer Activity of Microbial Biosurfactants Amphisin and Viscosinamide Against Melanoma Cells.Molecules (Basel, Switzerland) · 2026Article
- Surfactin Inhibits Osteoclast Differentiation by Negatively Regulating the Elk1-AP-1-NFATc1 Axis.Biomedicines · 2026Article
- Lipopeptides fromBiotech (Basel (Switzerland)) · 2026Article
- Marine-derived surfactin derivatives suppress collagen production and interfere with the HSP47-collagen interaction in preclinical models.Frontiers in pharmacology · 2026Article
- Hydrogen Sulfide: A Multitarget Therapeutic for Neuroinflammation in Neurodegenerative Diseases.Research (Washington, D.C.) · 2026Review
- Synthetic Linear Lipopeptides and Lipopeptoids Induce Apoptosis and Oxidative Stress: In Vitro Cytotoxicity and SAR Evaluation Against Cancer Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Bacillus velezensis MFF 2.2-derived lipopeptides modulate gut immune response in BALB/c mice maintaining mucosal integrity and systemic safety.Veterinary research communications · 2025Article
- Antimicrobial Activity ofInternational journal of molecular sciences · 2025Review
- Aspects of β-sitosterol's Pharmacology, Nutrition and Analysis.Current pharmaceutical biotechnology · 2025Review
- Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.Discover oncology · 2024Review
- Cell-Free Supernatant of Bacillus subtilis G2B9-Q Improves Intestinal Health and Modulates Immune Response to Promote Mouse Recovery in Clostridium perfringens Infection.Current microbiology · 2024Article
- Microbial lipopeptides: their pharmaceutical and biotechnological potential, applications, and way forward.World journal of microbiology & biotechnology · 2024Review
- Production, characterization and biomedical potential of biosurfactants produced by haloalkaliphilic archaea from Wadi El-Natrun, Egypt.Microbial cell factories · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surfactin, a cyclic lipopeptide biosurfactant produced by various strains of Bacillus genus, has been shown to induce cytotoxicity against many cancer types, such as Ehrlich ascites, breast and colon cancers, leukemia and hepatoma. Surfactin treatment can inhibit cancer progression by growth inhibition, cell cycle arrest, apoptosis, and metastasis arrest. Owing to the potent effect of surfactin on cancer cells, numerous studies have recently investigated the mechanisms that underlie its anticancer activity. The amphiphilic nature of surfactin allows its easy incorporation nano-formulations, such as polymeric nanoparticles, micelles, microemulsions, liposomes, to name a few. The use of nano-formulations offers the advantage of optimizing surfactin delivery for an improved anticancer therapy. This review focuses on the current knowledge of surfactin properties and biosynthesis; anticancer activity against different cancer models and the underlying mechanisms involved; as well as the potential application of nano-formulations for optimal surfactin delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.